Royal Philips has secured FDA 510(k) clearance for its Spectral CT Verida system, a significant advancement in imaging technology that integrates always-on spectral imaging with an AI-powered reconstruction engine. This next-generation system employs a third-generation Nano-panel Precise dual-layer detector to enhance image quality by reducing noise, allowing clinicians to customize image de-noising settings. With a remarkable capability to reconstruct 145 images per second, Verida can complete entire CT exams in under 30 seconds, effectively doubling throughput to up to 270 exams daily.

The introduction of Verida marks a pivotal shift in clinical imaging, particularly in radiology, cardiology, and oncology. By capturing both high- and low-energy data in a single acquisition, the system facilitates simultaneous access to conventional and spectral results, which enhances tissue characterization and material differentiation. This capability eliminates the need for pre-selection or repeat scans, thereby supporting first-time-right imaging and providing deeper clinical insights. The system is also designed to support low-dose lung cancer screening within established protocols, emphasizing its versatility across various patient demographics.

The implications of the Verida system are profound for the future of diagnostic imaging. By streamlining workflows and enhancing image quality, this technology not only improves patient throughput but also supports more informed clinical decision-making. As the field moves towards integrating advanced imaging modalities with AI, Verida sets a new standard for CT applications, potentially accelerating the adoption of AI in clinical settings and reshaping research paradigms in imaging technology.

Source: globenewswire.com